Race Oncology (ASX:RAC) filed an application with the Bellberry Human Research Ethics Committee for a phase 1 trial investigating the use of the RC220 bisantrene in combination with doxorubicin to potentially treat solid tumors, according to a Thursday filing made with the Australian bourse.
Once approved, the biopharmaceutical firm will activate the first trial site in New South Wales, with an additional 10 sites to follow, the filing said.
Patient recruitment for the trial is scheduled for the first quarter of next year, the filing added.
The company's shares surged past 9% in recent Thursday trade.
Price (AUD): $1.41, Change: $+0.12, Percent Change: +9.33%
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。